Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neocarzinostatin chromophore is the cytotoxic small-molecule component of the antitumor antibiotic neocarzinostatin. It is a naphthoate ester and enediyne natural product produced by *Streptomyces* species. The chromophore is tightly but non-covalently bound to a 113-amino acid apoprotein in the native complex; this protein protects the highly labile and reactive chromophore until it reaches its target. Upon release—often triggered by intracellular thiols—the chromophore undergoes activation (including Bergman cyclization), generating a benzenoid diradical that induces single- and double-strand DNA breaks via intercalation and radical-mediated cleavage. This results in potent inhibition of DNA synthesis and cell death. The compound exhibits both antitumor activity (notably used clinically in Japan for liver cancer) and antibiotic activity against Gram-positive bacteria[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Neocarzinostatin chromophore.